Familial Chylomicronemia Syndrome Market Expected to Experience Major Growth by 2034, According to DelveInsight | Ionis Pharma, Novartis, Akcea Therapeutics, Arrowhead Pharma, Visirna Therapeutics

DelveInsight’s “Familial Chylomicronemia Syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Familial Chylomicronemia Syndrome, historical and forecasted epidemiology as well as the Familial Chylomicronemia Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Familial Chylomicronemia Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Familial Chylomicronemia Syndrome Market Forecast

Some of the key facts of the Familial Chylomicronemia Syndrome Market Report: 

• The Familial Chylomicronemia Syndrome market size was valued approximately ~USD 15 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In Noevmber 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational therapy, plozasiran, aimed at treating familial chylomicronemia syndrome (FCS). FCS is a severe and rare genetic condition that currently lacks FDA-approved treatments. The company also plans to file for regulatory approval of plozasiran with other authorities in 2025.

• In April 2024, Ionis Pharmaceuticals is seeking regulatory approval for its lead candidate, olezarsen, following its success in achieving the primary endpoint in a pivotal trial for adults with familial chylomicronemia syndrome (FCS). The Phase III Balance trial, a global, multicenter, randomized, double-blind, placebo-controlled study (NCT04568434), included 66 participants aged 18 and older with confirmed FCS. Patients received olezarsen at doses of 80mg or 50mg, or a placebo, administered once every four weeks over a 53-week period.

• DelveInsight’s estimates indicate that the US accounted for 65% of the diagnosed prevalent FCS cases in 2022. The diagnosed prevalence of Familial Chylomicronemia Syndrome is projected to increase during the forecast period (2023–2034).

• In 2022, the EU4 and the UK together represented approximately 23% of the diagnosed prevalent cases of Familial Chylomicronemia Syndrome (FCS) across the seven major markets (7MM).

• In 2022, Germany had the highest diagnosed prevalent population of FCS among the EU4 and the UK, with nearly 135 cases, followed by France and the UK. Conversely, Spain had the lowest diagnosed prevalent population of FCS within this group.

• In Japan, there were approximately 4,886k diagnosed prevalent cases of Familial Chylomicronemia Syndrome in 2022. The number of cases is expected to grow at a significant compound annual growth rate (CAGR).

• Key Familial Chylomicronemia Syndrome Companies: Arrowhead Pharma, Visirna Therapeutics HK Limited, Ionis Pharmac, Novartis, Akcea Therapeutics, and others

• Key Familial Chylomicronemia Syndrome Therapies: ARO-APOC3, VSA001 injection, Olezarsen, LCQ908, AKCEA-ANGPTL3-LRx, Volanesorsen, Plozasiran, and others

• The Familial Chylomicronemia Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Familial Chylomicronemia Syndrome pipeline products will significantly revolutionize the Familial Chylomicronemia Syndrome market dynamics.

Familial Chylomicronemia Syndrome Overview

Familial Chylomicronemia Syndrome (FCS) is a rare genetic disorder characterized by the body’s inability to properly break down fats, leading to extremely high levels of triglycerides in the blood. This condition results from a deficiency or dysfunction of lipoprotein lipase (LPL), an enzyme crucial for the metabolism of chylomicrons, which are lipoproteins that transport dietary fats in the blood.

Get a Free sample for the Familial Chylomicronemia Syndrome Market Report:

https://www.delveinsight.com/report-store/familial-chylomicronemia-syndrome-market

Familial Chylomicronemia Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Familial Chylomicronemia Syndrome Epidemiology Segmentation:

The Familial Chylomicronemia Syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Familial Chylomicronemia Syndrome

• Prevalent Cases of Familial Chylomicronemia Syndrome by severity

• Gender-specific Prevalence of Familial Chylomicronemia Syndrome

• Diagnosed Cases of Episodic and Chronic Familial Chylomicronemia Syndrome

Download the report to understand which factors are driving Familial Chylomicronemia Syndrome epidemiology trends @ Familial Chylomicronemia Syndrome Epidemiology Forecast

Familial Chylomicronemia Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Familial Chylomicronemia Syndrome market or expected to get launched during the study period. The analysis covers Familial Chylomicronemia Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Familial Chylomicronemia Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Familial Chylomicronemia Syndrome Therapies and Key Companies

• ARO-APOC3: Arrowhead Pharma

• VSA001 injection: Visirna Therapeutics HK Limited

• Olezarsen: Ionis Pharmac

• LCQ908: Novartis

• AKCEA-ANGPTL3-LRx: Akcea Therapeutics

• Volanesorsen: Akcea Therapeutics

• Plozasiran: Arrowhead Pharmaceuticals

Discover more about therapies set to grab major Familial Chylomicronemia Syndrome market share @ Familial Chylomicronemia Syndrome Treatment Market

Scope of the Familial Chylomicronemia Syndrome Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Familial Chylomicronemia Syndrome Companies: Arrowhead Pharma, Visirna Therapeutics HK Limited, Ionis Pharmac, Novartis, Akcea Therapeutics, and others

• Key Familial Chylomicronemia Syndrome Therapies: ARO-APOC3, VSA001 injection, Olezarsen, LCQ908, AKCEA-ANGPTL3-LRx, Volanesorsen, Plozasiran, and others

• Familial Chylomicronemia Syndrome Therapeutic Assessment: Familial Chylomicronemia Syndrome current marketed and Familial Chylomicronemia Syndrome emerging therapies

• Familial Chylomicronemia Syndrome Market Dynamics: Familial Chylomicronemia Syndrome market drivers and Familial Chylomicronemia Syndrome market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Familial Chylomicronemia Syndrome Unmet Needs, KOL’s views, Analyst’s views, Familial Chylomicronemia Syndrome Market Access and Reimbursement 

To know more about Familial Chylomicronemia Syndrome companies working in the treatment market, visit @ Familial Chylomicronemia Syndrome Clinical Trials and Treatment

Table of Contents 

1. Familial Chylomicronemia Syndrome Market Report Introduction

2. Executive Summary for Familial Chylomicronemia Syndrome

3. SWOT analysis of Familial Chylomicronemia Syndrome

4. Familial Chylomicronemia Syndrome Patient Share (%) Overview at a Glance

5. Familial Chylomicronemia Syndrome Market Overview at a Glance

6. Familial Chylomicronemia Syndrome Disease Background and Overview

7. Familial Chylomicronemia Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Familial Chylomicronemia Syndrome 

9. Familial Chylomicronemia Syndrome Current Treatment and Medical Practices

10. Familial Chylomicronemia Syndrome Unmet Needs

11. Familial Chylomicronemia Syndrome Emerging Therapies

12. Familial Chylomicronemia Syndrome Market Outlook

13. Country-Wise Familial Chylomicronemia Syndrome Market Analysis (2020–2034)

14. Familial Chylomicronemia Syndrome Market Access and Reimbursement of Therapies

15. Familial Chylomicronemia Syndrome Market Drivers

16. Familial Chylomicronemia Syndrome Market Barriers

17.  Familial Chylomicronemia Syndrome Appendix

18. Familial Chylomicronemia Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/